About: Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $44.62 (+0.11%)
COAGNASDAQHemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. Common Stock share price
COAG price activity
Last Price
$44.620
Change (24hr)
0.05 USD (0.11%)
Volume
304.75K
Volume (4w avg)
-
Open
$44.77
Day Range
$43.12 - $46.20
Previous Close
$44.57
Last Trade
09 Sep, 7:34 pm GMT+0
Delayed
09 Sep, 7:34 pm GMT+0
COAG price performance
Delayed
09 Sep, 7:34 pm GMT+0
COAG Market Signals